FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1952-1961 November 4, 2004 Number 19 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Mitch, W. E. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background Few studies have directly compared the renoprotective effects of angiotensin II–receptor blockers and angiotensin-converting–enzyme (ACE) inhibitors in persons with type 2 diabetes.

Methods In this prospective, multicenter, double-blind, five-year study, we randomly assigned 250 subjects with type 2 diabetes and early nephropathy to receive either the angiotensin II–receptor blocker telmisartan (80 mg daily, in 120 subjects) or the ACE inhibitor enalapril (20 mg daily, in 130 subjects). The primary end point was the change in the glomerular filtration rate (determined by measuring the plasma clearance of iohexol) between the baseline value and the last available value during the five-year treatment period. Secondary end points included the annual changes in the glomerular filtration rate, serum creatinine level, urinary albumin excretion, and blood pressure; the rates of end-stage renal disease and cardiovascular events; and the rate of death from all causes.

Results After five years, the change in the glomerular filtration rate was –17.9 ml per minute per 1.73 m² of body-surface area, where the minus sign denotes a decrement, with telmisartan (in 103 subjects), as compared with –14.9 ml per minute per 1.73 m² with enalapril (in 113 subjects), for a treatment difference of –3.0 ml per minute per 1.73 m² (95 percent confidence interval, –7.6 to 1.6 ml per minute per 1.73 m²). The lower boundary of the confidence interval, in favor of enalapril, was greater than the predefined margin of –10.0 ml per minute per 1.73 m², indicating that telmisartan was not inferior to enalapril. The effects of the two agents on the secondary end points were not significantly different after five years.

Conclusions Telmisartan is not inferior to enalapril in providing long-term renoprotection in persons with type 2 diabetes. These findings do not necessarily apply to persons with more advanced nephropathy, but they support the clinical equivalence of angiotensin II–receptor blockers and ACE inhibitors in persons with conditions that place them at high risk for cardiovascular events.

Source Information

From the Division of Medical Sciences, University of Birmingham and Birmingham Heartlands and Solihull National Health Service Trust (Teaching), Birmingham, United Kingdom (A.H.B., S.C.B.); the Department of Internal Medicine, Bosch Medicentre, Den Bosch, the Netherlands (P.B.); University Hospital, Linköping, Linköping, Sweden (B.K.); the Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark (S.M.); University Hospital of Oslo, Oslo (J.J.); and the Department of Internal Medicine, Tampere University Hospital, Tampere, Finland (J.M.).

Address reprint requests to Dr. Barnett at the Undergraduate Center, Birmingham Heartlands Hospital, Bordesley Green E., Birmingham B9 5SS, United Kingdom, or at anthony.barnett{at}heartsol.wmids.nhs.uk.

Full Text of this Article

Related Letters:

Telmisartan vs. Enalapril in Type 2 Diabetes
Asgari A. A., Sarvghadi F., Zahed N., Parving H.-H., Hovind P., Rossing P., Loewenstein J. E., Bain S. C., Barnett A.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:835-836, Feb 24, 2005. Correspondence

This article has been cited by other articles:

• Unger, T. (2009). The rationale for choosing telmisartan and ramipril in the ONTARGET programme. Eur Heart J Suppl 11: F3-F8 [Abstract] [Full Text]  
• Chung, A. W.Y., Yang, H.H. C., Sigrist, M. K., Brin, G., Chum, E., Gourlay, W. A., Levin, A. (2009). Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease. Cardiovasc Res 84: 494-504 [Abstract] [Full Text]  
• Dobre, D., Lambers Heerspink, H. J., de Zeeuw, D. (2009). Reducing cardiovascular risk: protecting the kidney. Eur Heart J Suppl 11: F39-F46 [Abstract] [Full Text]  
• Postma, M. J., de Zeeuw, D. (2009). The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus. Nephrol Dial Transplant 24: 2975-2983 [Full Text]  
• O'Hare, A. M., Kaufman, J. S., Covinsky, K. E., Landefeld, C. S., McFarland, L. V., Larson, E. B. (2009). Current Guidelines for Using Angiotensin-Converting Enzyme Inhibitors and Angiotensin II-Receptor Antagonists in Chronic Kidney Disease: Is the Evidence Base Relevant to Older Adults?. ANN INTERN MED 150: 717-724 [Abstract] [Full Text]  
• Tian, Q., Miyazaki, R., Ichiki, T., Imayama, I., Inanaga, K., Ohtsubo, H., Yano, K., Takeda, K., Sunagawa, K. (2009). Inhibition of Tumor Necrosis Factor-{alpha}-Induced Interleukin-6 Expression by Telmisartan Through Cross-Talk of Peroxisome Proliferator-Activated Receptor-{gamma} With Nuclear Factor {kappa}B and CCAAT/Enhancer-Binding Protein-{beta}. Hypertension 53: 798-804 [Abstract] [Full Text]  
• Macconi, D., Sangalli, F., Bonomelli, M., Conti, S., Condorelli, L., Gagliardini, E., Remuzzi, G., Remuzzi, A. (2009). Podocyte Repopulation Contributes to Regression of Glomerular Injury Induced by Ace Inhibition. Am. J. Pathol. 174: 797-807 [Abstract] [Full Text]  
• Kim, S.-Y., Park, K.-H., Gul, R., Jang, K. Y., Kim, U.-H. (2009). Role of kidney ADP-ribosyl cyclase in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 296: F291-F297 [Abstract] [Full Text]  
• Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., Eckel, R. H. (2008). The Metabolic Syndrome. Endocr. Rev. 29: 777-822 [Abstract] [Full Text]  
• Wright, J., Vardhan, A. (2008). Review: The problem of diabetic nephropathy and practical prevention of its progression. British Journal of Diabetes & Vascular Disease 8: 272-277 [Abstract]  
• Wu, I., Parikh, C. R. (2008). Screening for Kidney Diseases: Older Measures versus Novel Biomarkers. CJASN 3: 1895-1901 [Abstract] [Full Text]  
• Xie, D., Joffe, M. M., Brunelli, S. M., Beck, G., Chertow, G. M., Fink, J. C., Greene, T., Hsu, C.-y., Kusek, J. W., Landis, R., Lash, J., Levey, A. S., O'Conner, A., Ojo, A., Rahman, M., Townsend, R. R., Wang, H., Feldman, H. I. (2008). A Comparison of Change in Measured and Estimated Glomerular Filtration Rate in Patients with Nondiabetic Kidney Disease. CJASN 3: 1332-1338 [Abstract] [Full Text]  
• Schindler, C. (2008). ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET. Ther Adv Cardiovasc Dis 2: 233-248 [Abstract]  
• Postma, M. J., Boersma, C., Gansevoort, R. T. (2008). Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria. Nephrol Dial Transplant 23: 1103-1106 [Full Text]  
• Kopp, U. C., Cicha, M. Z., Yorek, M. A. (2008). Impaired responsiveness of renal sensory nerves in streptozotocin-treated rats and obese Zucker diabetic fatty rats: role of angiotensin. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294: R858-R866 [Abstract] [Full Text]  
• Day, C., Hewins, P., Hildebrand, S., Sheikh, L., Taylor, G., Kilby, M., Lipkin, G. (2008). The role of renal biopsy in women with kidney disease identified in pregnancy. Nephrol Dial Transplant 23: 201-206 [Abstract] [Full Text]  
• Matchar, D. B., McCrory, D. C., Orlando, L. A., Patel, M. R., Patel, U. D., Patwardhan, M. B., Powers, B., Samsa, G. P., Gray, R. N. (2008). Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension. ANN INTERN MED 148: 16-29 [Abstract] [Full Text]  
• Kunz, R., Friedrich, C., Wolbers, M., Mann, J. F.E. (2008). Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease. ANN INTERN MED 148: 30-48 [Abstract] [Full Text]  
• Bakris, G. L. (2008). Slowing Nephropathy Progression: Focus on Proteinuria Reduction. CJASN 3: S3-S10 [Abstract] [Full Text]  
• Milionis, H. J, Kostapanos, M. S, Vakalis, K., Theodorou, I., Bouba, I., Kalaitzidis, R., Georgiou, I., Elisaf, M. S, Siamopoulos, K. C (2007). Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome. Journal of Renin-Angiotensin-Aldosterone System 8: 181-189 [Abstract]  
• Burnier, M. (2007). Blockade of the renin-angiotensin system for renal future perspectives protection: from history to future perspective. Journal of Renin-Angiotensin-Aldosterone System 8: 208-211  
• Schindler, C. (2007). Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?. Ther Adv Cardiovasc Dis 1: 7-26 [Abstract]  
• Lamb, E. J., Fogarty, D. G., Murchie, P., Ritz, E., Isles, C., Jardine, A., Goldsmith, D., Cassidy, M., O'Donoghue, D., McIntyre, N., Vale, L., Feehally, J., El Nahas, M. (2007). Speaker Abstracts: Tuesday, 6 February 2007. Nephrol Dial Transplant 22: ix45-ix53 [Full Text]  
• Cavanaugh, K. L. (2007). Diabetes Management Issues for Patients With Chronic Kidney Disease. Clin. Diabetes 25: 90-97 [Abstract] [Full Text]  
• Wang, J.-G., Li, Y., Franklin, S. S., Safar, M. (2007). Prevention of Stroke and Myocardial Infarction by Amlodipine and Angiotensin Receptor Blockers: A Quantitative Overview. Hypertension 50: 181-188 [Abstract] [Full Text]  
• Yano, N., Suzuki, D., Endoh, M., Zhao, T. C., Padbury, J. F., Tseng, Y.-T. (2007). A Novel Phosphoinositide 3-Kinase-dependent Pathway for Angiotensin II/AT-1 Receptor-mediated Induction of Collagen Synthesis in MES-13 Mesangial Cells. J. Biol. Chem. 282: 18819-18830 [Abstract] [Full Text]  
• Schmieder, R. E., Delles, C., Mimran, A., Fauvel, J. P., Ruilope, L. M. (2007). Impact of Telmisartan Versus Ramipril on Renal Endothelial Function in Patients With Hypertension and Type 2 Diabetes. Diabetes Care 30: 1351-1356 [Abstract] [Full Text]  
• Kamper, A.-L. (2007). The importance of a correct evaluation of progression in studies on chronic kidney disease. Nephrol Dial Transplant 22: 3-5 [Full Text]  
• Glassock, R. J. (2006). Prevention of Microalbuminuria in Type 2 Diabetes: Millimeters or Milligrams?. J. Am. Soc. Nephrol. 17: 3276-3278 [Full Text]  
• Fernandez-Juarez, G., Barrio, V., de Vinuesa, S. G., Goicoechea, M., Praga, M., Luno, J. (2006). Dual Blockade of the Renin-Angiotensin System in the Progression of Renal Disease: The Need for More Clinical Trials. J. Am. Soc. Nephrol. 17: S250-S254 [Abstract] [Full Text]  
• Rossing, P., Parving, H.-H., de Zeeuw, D. (2006). Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?. Nephrol Dial Transplant 21: 2354-2357 [Full Text]  
• Tsuyuki, R. T., McDonald, M. A. (2006). Response to Tsuyuki and McDonald. Circulation 114: 855-860 [Full Text]  
• Tonelli, M., Sacks, F., Pfeffer, M., Gao, Z.H., Curhan, G., for the Cholesterol and Recurrent Events (CARE) Tr, , Rossing, P., Rossing, K., Gaede, P., Pedersen, O., Parving, H.-H. (2006). Serum Phosphate: A Novel Cardiovascular Risk Factor Even in Nonrenal Patients: Relation between Serum Phosphate Level and Cardiovascular Event Rate in People with Coronary Disease. Circulation 112: 2627-2633, 2005. J. Am. Soc. Nephrol. 17: 2077-2085 [Full Text]  
• Navaneethan, S. D., Querques, M., Bonifati, C., Strippoli, G. F. M. (2006). Antihypertensive Agents in Patients With Diabetes: Trade-off Between Renal and Cardiovascular Protection.. The Diabetes Educator 32: 596-602 [Abstract] [Full Text]  
• Dobesh, P. P. (2006). Managing hypertension in patients with type 2 diabetes mellitus.. Am J Health Syst Pharm 63: 1140-1149 [Abstract] [Full Text]  
• Sever, P. S., Poulter, N. R., Elliott, W. J., Jonsson, M. C., Black, H. R., Sever, P. S., Poulter, N. R., Elliott, W. J., Jonsson, M. C., Black, H. R. (2006). Blood Pressure Reduction Is Not the Only Determinant of Outcome. Circulation 113: 2754-2774 [Full Text]  
• Volpe, M., Tocci, G., Pagannone, E. (2006). Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System.. J. Am. Soc. Nephrol. 17: S36-S43 [Abstract] [Full Text]  
• Remuzzi, G., Macia, M., Ruggenenti, P. (2006). Prevention and Treatment of Diabetic Renal Disease in Type 2 Diabetes: The BENEDICT Study. J. Am. Soc. Nephrol. 17: S90-S97 [Abstract] [Full Text]  
• Barnett, A. (2006). Preventing Renal Complications in Type 2 Diabetes: Results of the Diabetics Exposed to Telmisartan and Enalapril Trial. J. Am. Soc. Nephrol. 17: S132-S135 [Abstract] [Full Text]  
• Ibsen, H., Olsen, M. H., Wachtell, K., Borch-Johnsen, K., Lindholm, L. H., Mogensen, C. E., Dahlof, B., Snapinn, S. M., Wan, Y., Lyle, P. A. (2006). Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?: The LIFE study.. Diabetes Care 29: 595-600 [Abstract] [Full Text]  
• Nickenig, G., Ostergren, J., Struijker-Boudier, H. (2006). Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers. Journal of Renin-Angiotensin-Aldosterone System 7: S1-S7 [Abstract]  
• Barnett, A. H (2006). The challenge of tackling cardiovascular outcomes. British Journal of Diabetes & Vascular Disease 6: S12-S16 [Abstract]  
• Kimmel, P. L. (2006). Update in nephrology and hypertension.. ANN INTERN MED 144: 281-285 [Full Text]  
• Stults, B., Jones, R. E. (2006). Management of Hypertension in Diabetes. Diabetes Spectr. 19: 25-31 [Abstract] [Full Text]  
• Nosadini, R., Velussi, M., Brocco, E., Abaterusso, C., Carraro, A., Piarulli, F., Morgia, G., Satta, A., Faedda, R., Abhyankar, A., Luthman, H., Tonolo, G. (2006). Increased Renal Arterial Resistance Predicts the Course of Renal Function in Type 2 Diabetes With Microalbuminuria. Diabetes 55: 234-239 [Abstract] [Full Text]  
• Berl, T., Henrich, W. (2006). Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment. CJASN 1: 8-18 [Full Text]  
• Brugts, J. J., Knetsch, A. M., Mattace-Raso, F. U. S., Hofman, A., Witteman, J. C. M. (2005). Renal Function and Risk of Myocardial Infarction in an Elderly Population: The Rotterdam Study. Arch Intern Med 165: 2659-2665 [Abstract] [Full Text]  
• Barr, D. A. (2005). The Practitioner's Dilemma: Can We Use a Patient's Race To Predict Genetics, Ancestry, and the Expected Outcomes of Treatment?. ANN INTERN MED 143: 809-815 [Abstract] [Full Text]  
• Tuttle, K. R., Bakris, G. L., Toto, R. D., McGill, J. B., Hu, K., Anderson, P. W. (2005). The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes. Diabetes Care 28: 2686-2690 [Abstract] [Full Text]  
• Wartofsky, L. (2005). Update in Endocrinology. ANN INTERN MED 143: 673-682 [Full Text]  
• Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C. Jr, Spertus, J. A., Costa, F. (2005). Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752 [Full Text]  
• McDonald, M. A, Simpson, S. H, Ezekowitz, J. A, Gyenes, G., Tsuyuki, R. T (2005). Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 331: 873- [Abstract] [Full Text]  
• Verma, S., Leiter, L. A., Lonn, E. M., Strauss, M. H. (2005). Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE. Eur Heart J 26: 1347-1349 [Full Text]  
• (2005). Hypertension in type 2 diabetes - targeting angiotensin. DTB 43: 41-45 [Abstract] [Full Text]  
• Palmer, A. J., Tucker, D. M. D., Valentine, W. J., Roze, S., Gabriel, S., Cordonnier, D. J. (2005). Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrol Dial Transplant 20: 1103-1109 [Abstract] [Full Text]  
• Hippisley-Cox, J., Coupland, C. (2005). Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ 330: 1059-1063 [Abstract] [Full Text]  
• Xu, Z.-G., Lanting, L., Vaziri, N. D., Li, Z., Sepassi, L., Rodriguez-Iturbe, B., Natarajan, R. (2005). Upregulation of Angiotensin II Type 1 Receptor, Inflammatory Mediators, and Enzymes of Arachidonate Metabolism in Obese Zucker Rat Kidney: Reversal by Angiotensin II Type 1 Receptor Blockade. Circulation 111: 1962-1969 [Abstract] [Full Text]  
• (2005). Lipid and blood pressure control reduce CVD risk. DOC News 2: 5-5 [Full Text]  
• Fioretto, P., Solini, A. (2005). Antihypertensive Treatment and Multifactorial Approach for Renal Protection in Diabetes. J. Am. Soc. Nephrol. 16: S18-S21 [Abstract] [Full Text]  
• Asgari, A. A., Sarvghadi, F., Zahed, N., Parving, H.-H., Hovind, P., Rossing, P., Loewenstein, J. E., Bain, S. C., Barnett, A. (2005). Telmisartan vs. Enalapril in Type 2 Diabetes. NEJM 352: 835-836 [Full Text]  
• Barnett, A. (2005). Telmisartan and enalapril in type 2 diabetes: Diabetics Exposed to Telmisartan and Enalapril (DETAIL) study. British Journal of Diabetes & Vascular Disease 5: 24-26  
• (2004). ARB or ACE Inhibitor for Patients with Diabetic Nephropathy?. Journal Watch Cardiology 2004: 3-3 [Full Text]  
• (2004). ACE Inhibitors vs. ARBs in Patients with Diabetic Nephropathy: A New Study. JWatch General 2004: 3-3 [Full Text]